HC Wainwright Lowers Selecta Biosciences (NASDAQ:SELB) Price Target to $4.00

Selecta Biosciences (NASDAQ:SELBGet Rating) had its price objective trimmed by HC Wainwright from $6.00 to $4.00 in a research note published on Tuesday morning, The Fly reports. The firm currently has a buy rating on the stock.

Several other equities research analysts also recently weighed in on SELB. TheStreet upgraded Selecta Biosciences from a d rating to a c- rating in a report on Wednesday, May 25th. SVB Leerink assumed coverage on Selecta Biosciences in a report on Monday, June 6th. They set an outperform rating and a $7.00 price objective on the stock. Needham & Company LLC reduced their price objective on Selecta Biosciences from $6.00 to $5.00 and set a buy rating on the stock in a report on Tuesday, June 14th. Finally, StockNews.com downgraded Selecta Biosciences from a buy rating to a hold rating in a report on Saturday, May 14th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of Moderate Buy and a consensus price target of $4.88.

Shares of SELB stock opened at $1.40 on Tuesday. The company has a debt-to-equity ratio of 0.45, a current ratio of 3.31 and a quick ratio of 3.31. The stock’s 50 day simple moving average is $0.91 and its two-hundred day simple moving average is $1.78. Selecta Biosciences has a 1 year low of $0.65 and a 1 year high of $4.70. The company has a market cap of $212.53 million, a PE ratio of -28.00 and a beta of 1.35.

Selecta Biosciences (NASDAQ:SELBGet Rating) last issued its quarterly earnings results on Thursday, May 5th. The company reported $0.08 earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.19. Selecta Biosciences had a negative return on equity of 33.56% and a net margin of 25.63%. During the same period in the prior year, the business earned ($0.22) EPS. Equities research analysts expect that Selecta Biosciences will post -0.21 EPS for the current year.

In related news, Director Carrie Smith Cox bought 130,000 shares of the company’s stock in a transaction on Monday, June 13th. The shares were acquired at an average price of $1.15 per share, with a total value of $149,500.00. Following the transaction, the director now owns 212,881 shares of the company’s stock, valued at $244,813.15. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Timothy C. Barabe acquired 50,000 shares of the stock in a transaction dated Monday, May 9th. The stock was acquired at an average cost of $0.77 per share, with a total value of $38,500.00. Following the transaction, the director now directly owns 250,013 shares in the company, valued at $192,510.01. The disclosure for this purchase can be found here. 30.50% of the stock is currently owned by company insiders.

Institutional investors have recently bought and sold shares of the company. Blair William & Co. IL acquired a new stake in shares of Selecta Biosciences in the 4th quarter worth $49,000. Lazard Asset Management LLC raised its stake in Selecta Biosciences by 46.8% in the 4th quarter. Lazard Asset Management LLC now owns 18,568 shares of the company’s stock worth $60,000 after acquiring an additional 5,919 shares during the last quarter. Beacon Pointe Advisors LLC purchased a new position in Selecta Biosciences in the 3rd quarter worth $79,000. Eqis Capital Management Inc. purchased a new position in Selecta Biosciences in the 1st quarter worth $30,000. Finally, Personal CFO Solutions LLC raised its stake in Selecta Biosciences by 49.0% in the 3rd quarter. Personal CFO Solutions LLC now owns 43,339 shares of the company’s stock worth $180,000 after acquiring an additional 14,256 shares during the last quarter. 72.62% of the stock is owned by hedge funds and other institutional investors.

Selecta Biosciences Company Profile (Get Rating)

Selecta Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in preclinical stage to improve the treatment of methylmalonic acidemia.

Read More

The Fly logo

Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.